An update on diagnosing and treating urinary bladder transitional cell carcinoma in dogs - Veterinary Medicine
  • SEARCH:
Medicine Center
DVM Veterinary Medicine Featuring Information from:

ADVERTISEMENT

An update on diagnosing and treating urinary bladder transitional cell carcinoma in dogs
These tumors in dogs are difficult to completely resect, so the prognosis for long-term survival is guarded. But new avenues of treatment are being discovered, and treatment protocols already in place can extend and enhance dogs' lives.


VETERINARY MEDICINE


42. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.

43. Sharifi R, Lee M, Clayton M, et al. Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. Anticancer Drugs 1991;2:153-157.

44. Namasivayam S, Whelan P. Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study. Br J Urol 1995;75:740-743.

45. Poirier VJ, Forrest LJ, Adams WM, et al. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study. J Am Anim Hosp Assoc 2004;40:131-136.

46. Withrow SJ, Gillette EL, Hoopes PJ, et al. Intraoperative irradiation of 16 spontaneously occurring canine neoplasms. Vet Surg 1989;18:7-11.

47. Walker M, Breider M. Intraoperative radiotherapy of canine bladder cancer. Vet Radiol 1987;28:200-204.

48. Anderson CR, McNiel EA, Gillette EL, et al. Late complications of pelvic irradiation in 16 dogs. Vet Radiol Ultrasound 2002;43:187-192.

49. de Lorimier LP, Fan TM. Treating cancer pain in dogs and cats. Vet Med 2005;100:364-379.

50. Stiffler KS, McCrackin Stevenson MA, Cornell KK, et al. Clinical use of low-profile cystostomy tubes in four dogs and a cat. J Am Vet Med Assoc 2003;223:325-329.

51. Salinardi BJ, Marks SL, Davidson JR, et al. The use of a low-profile cystostomy tube to relieve urethral obstruction in a dog. J Am Anim Hosp Assoc 2003;39:403-405.

52. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.

53. Thrall DE, LaRue SM. Palliative radiation therapy. Semin Vet Med Surg (Small Anim) 1995;10:205-208.

54. Kassouf W, Dinney CP, Brown G, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005;65:10524-10535.

55. Ridgway TD, Lucroy MD. Phototoxic effects of 635-nm light on canine transitional cell carcinoma cells incubated with 5-aminolevulinic acid. Am J Vet Res 2003;64:131-136.

56. Skyrme RJ, French AJ, Datta SN, et al. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int 2005;95:1206-1210.

57. Lamm DL, McGee WR, Hale K. Bladder cancer: current optimal intravesical treatment. Urol Nurs 2005;25:323-326.

58. Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999;5:2629-2637.

59. van der Meijden AP, Steerenberg PA, de Jong WH, et al. The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder. Urol Res 1986;14:207-210.

60. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. J Am Med Assoc 2001;285:324-328.

61. Henry CJ, University of Missouri, Columbia: Personal communication, April 2006.


ADVERTISEMENT


Click here